VivoSeq
Other

Nerve Block

0

Pipeline Programs

13

Active Trials

2

Companies Involved

Nerve Block is an early-stage landscape with 0 programs across 2 companies. The most active players are Pacira Pharmaceuticals, Inc, Heron Therapeutics.

Pipeline Metrics

Competitive Density

30/100

Pipeline Velocity

22/100

Mech. Concentration

N/A

Completion Rate

77/100

Attrition Rate

16/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

95

clinical trials

Completed50 · 53%
Unknown status17 · 18%
Terminated10 · 11%
Recruiting7 · 7%
Withdrawn5 · 5%
Not yet recruiting4 · 4%
Other2 · 2%

Trial Activity

95 trials

Evaluation of Trigeminal Nerve Blockade
Active, not recruiting·UUniversity of Florida·Phase 4·NCT03632044·40 enrolled
Clinical Observation of Bupivacaine Liposome for Lower Extremity Nerve Block
Not yet recruiting··Phase 2·NCT07366905·60 enrolled
Dorsal Nerve Block and Caudal Block in Hypospedius Repair in Children
Not yet recruiting··Phase 1·NCT06500286·103 enrolled
Page 1 of 7

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)